Clinical trial
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
NCT00149292 · Denovo Biopharma LLC, Industry · Completed
Key facts
| NCT number | NCT00149292 |
|---|---|
| Title | Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo |
| Official title | A Randomized, Double-Blind Comparison of LY2140023, Olanzapine, and Placebo in the Treatment of Patients With Schizophrenia |
| Lead sponsor | Denovo Biopharma LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | LY2140023, olanzapine, placebo |
| Enrollment | 195 |
| Start date | Aug 23, 2005 |
| Primary completion | Jul 17, 2006 |
| Completion | Jul 17, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Aug 20, 2021 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: